Roivant Sciences Ltd
F:87S
Intrinsic Value
Roivant Sciences Ltd. engages in the biopharmaceutical business, which engages in the development of transformative medicine. [ Read More ]
The intrinsic value of one
87S
stock under the Base Case scenario is
3.62
EUR.
Compared to the current market price of 10.06 EUR,
Roivant Sciences Ltd
is
Overvalued by 64%.
87S's market price has consistently been higher than its intrinsic value.This persistent overvaluation suggests the market may be overly optimistic about
87S or that its price is influenced by factors unrelated to fundamentals.
Roivant Sciences Ltd's market capitalization is 8.1B EUR.
87S stock price is 10.06 EUR.
87S stock (3.62 EUR) is 64% less than its price (10.06 EUR).
87S. Open DCF Valuation
87S stock (3.62 EUR) is 64% less than its price (10.06 EUR). Open Relative Valuation
87S has upside potential of 41% compared to the average analyst price target.
Open Wall St Estimates
87S's Revenue has grown by an exceptional 186% over the past 12 months.
87S has negative Operating Income for the last twelve months.
87S has positive Net Income for the last twelve months.
87S's ROE (Return on Equity) for the past 12 months is very high and is equal to 127%.
87S's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -173%.
87S has positive Gross Profit for the last twelve months.
87S's Revenue is forecast to grow at a rate of 81% per year over the next 3 years.
87S's Altman Z-Score is very high and is equal to 3.54.
87S has negative Free Cash Flow for the last twelve months.
87S's D/E (Debt to Equity) is very low and is equal to 0.07.
87S has negative three-year average ROE (Return on Equity): -47%. The company is not efficient at transforming stockholders' equity into net income.
87S has negative three-year average ROIC (Return on Invested Capital): -217%. The company is not efficient at using invested capital to generate operating income.
87S's short-term assets (7B USD) exceed its short-term liabilties (245m USD).
87S's long-term assets (7B USD) exceed its long-term liabilties (1B USD).
87S has negative Net Debt. This means that the company has more cash and short-term investments (7B USD) than debt (403m USD).
Valuation Backtest
Roivant Sciences Ltd
Run backtest to discover the historical profit from buying and selling
87S
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Roivant Sciences Ltd
Balance Sheet Decomposition
Roivant Sciences Ltd
| Current Assets | 6.8B |
| Cash & Short-Term Investments | 6.7B |
| Receivables | 44.3m |
| Other Current Assets | 91.6m |
| Non-Current Assets | 505.9m |
| Long-Term Investments | 239.9m |
| PP&E | 68.8m |
| Intangibles | 150.4m |
| Other Non-Current Assets | 46.8m |
| Current Liabilities | 244.9m |
| Accounts Payable | 35.2m |
| Accrued Liabilities | 132.6m |
| Other Current Liabilities | 77m |
| Non-Current Liabilities | 978m |
| Long-Term Debt | 403.3m |
| Other Non-Current Liabilities | 574.7m |
Earnings Waterfall
Roivant Sciences Ltd
|
Revenue
|
123.2m
USD
|
|
Cost of Revenue
|
-15.3m
USD
|
|
Gross Profit
|
107.9m
USD
|
|
Operating Expenses
|
-1.2B
USD
|
|
Operating Income
|
-1.1B
USD
|
|
Other Expenses
|
5.5B
USD
|
|
Net Income
|
4.5B
USD
|
Free Cash Flow Analysis
Roivant Sciences Ltd
87S Profitability Score
Profitability Due Diligence
Roivant Sciences Ltd's profitability score is 35/100. The higher the profitability score, the more profitable the company is.
Score
Roivant Sciences Ltd's profitability score is 35/100. The higher the profitability score, the more profitable the company is.
87S Solvency Score
Solvency Due Diligence
Roivant Sciences Ltd's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Score
Roivant Sciences Ltd's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
87S Price Targets Summary
Roivant Sciences Ltd
According to Wall Street analysts, the average 1-year price target for
87S
is 14.18 EUR
with a low forecast of 10.59 EUR and a high forecast of 18.36 EUR.
Shareholder Return
87S Price
Roivant Sciences Ltd
| Average Annual Return | 25.58% |
| Standard Deviation of Annual Returns | 58.8% |
| Max Drawdown | -78% |
| Market Capitalization | 8.1B EUR |
| Shares Outstanding | 805 850 000 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Roivant Sciences Ltd
Country
Industry
Market Cap
Dividend Yield
Description
Roivant Sciences Ltd. engages in the biopharmaceutical business, which engages in the development of transformative medicine. The Company’s pipeline is focused on inflammation and immunology and includes VTAMA, a novel topical approved for the treatment of psoriasis and in development for the treatment of atopic dermatitis; batoclimab and IMVT-1402, fully human monoclonal antibodies targeting the neonatal Fc receptor (FcRn) in development across several IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody in development for ulcerative colitis and Crohn’s disease, in addition to various other therapies in various stages of clinical development. The firm advances its pipeline by creating nimble subsidiaries or Vants to develop and commercialize its medicines and technologies. The company also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business.
Officers
The intrinsic value of one
87S
stock under the Base Case scenario is
3.62
EUR.
Compared to the current market price of 10.06 EUR,
Roivant Sciences Ltd
is
Overvalued by 64%.
You don't have any saved screeners yet
